Key takeaways
Mira Pharmaceuticals Inc reported Phase 1 clinical data for Ketamir-2 that the company described as positive, and the news pushed MIRA shares up 5.1% in premarket trading. The trial was carried out as a randomized, double-blind, placebo-controlled study examining safety, tolerability and pharmacokinetics in healthy volunteers across single and multiple ascending dose cohorts.
Study conduct and safety profile
The Phase 1 study included 57 healthy participants. All enrolled subjects completed the protocol with no withdrawals. Mira reported no serious adverse events and no dose-limiting toxicities during the trial. Adverse events that were recorded were mostly mild in severity, and the incidence of such events was higher in the placebo arm than among those receiving Ketamir-2.
Pharmacokinetics and dosing implications
Pharmacokinetic evaluation showed rapid oral absorption of Ketamir-2 and a dose-proportional Cmax across the dose range tested. The parent compound exhibited an apparent half-life ranging from approximately 2.5 to 7 hours, while its active metabolite showed an approximate half-life of 7 to 9 hours. Mira stated that this pharmacokinetic profile may support once-daily administration, although further clinical evaluation will be required to confirm a dosing regimen.
Regulatory and development next steps
On the strength of the Phase 1 results, Mira is preparing to submit a Phase 2a clinical protocol to the U.S. Food and Drug Administration under its active Investigational New Drug application. The planned Phase 2a will be a proof-of-concept study intended to assess Ketamir-2 in patients suffering from moderate to severe chemotherapy-induced peripheral neuropathy, a condition for which no therapies are currently approved by the FDA.
Company commentary
Mira's leadership framed Ketamir-2 as designed to preserve the therapeutic potential of NMDA receptor modulation while reducing the dissociative effects associated with ketamine. Company management said the Phase 1 findings mark an important milestone as the program advances toward Phase 2a development.
Market context
The article noted an external projection that the global chemotherapy-induced peripheral neuropathy market could reach approximately $1.7 billion by 2035, as estimated by Spherical Insights & Consulting.
Implications for markets and investors
Positive early-stage clinical data and a clear next regulatory step under an active IND contributed to the premarket uptick in MIRA equity. Further clinical data from the planned Phase 2a trial will be necessary to determine therapeutic value in the intended patient population.